The Legal Practice Board’s decision to audit lawyers at a compensation firm following a complaint about paralegals allegedly engaging in unqualified legal practice has been quashed, with a court finding the law didn’t permit investigation of individual solicitors.
The Australian Competition and Consumer Commission has approved France-based Louis Dreyfus’ proposed acquisition of ASX-traded cotton gin operator Namoi Cotton, after accepting an undertaking that allayed its competition concerns.
Sydney-based wealth guru Dominique Grubisa has been banned from managing corporations for 18 months after an ASIC investigation found two companies she managed owed more than $300,000 to creditors.
Swiss fintech Temenos has partially won its bid to view legal advice received by the Northern Inland Credit Union in a lawsuit alleging the cloud banking provider made misleading representations during negotiations for the installation of a new core banking system.
The Queensland Court of Appeal has knocked back a challenge by jailed investment guru Dr Roger Munro to his conviction on three counts of fraud, which landed him a four-and-a-half month prison sentence.
Bondi wellness research company Doll House has copped a $197,000 penalty for terminating three disabled employees and re-engaging them as independent contractors in a ‘sham’ contracting arrangement.
An appeals court has knocked back builder Hanssenâs attempt to dodge a decade-old dispute over repairs to one of its residential buildings on constitutional grounds, saying the Perth company’s argument would precipitate an âextraordinaryâ result if accepted.
A judge has set aside a decision upholding misconduct findings against a former Australian National University PhD student, who was concerned the decision could affect his career prospects in the law.
An appeals court has knocked back a Melbourne barrister’s challenge to a decision that found him guilty of professional misconduct for making an unsubstantiated allegation of fraud in a costs dispute.Â
A judge has rejected Samsung Bioepis’ bid to discover research and development documents from Pfizer as it seeks to invalidate the drug giant’s patent for its blockbuster autoimmune drug Enbrel, agreeing with Pfizer that it may be “no more than an exercise in fishing”.